Navigation Links
Avicena Reports Second Quarter 2007 Results
Date:8/31/2007

PALO ALTO, Calif., Aug. 31 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, today announced financial results for the three month period ended June 30, 2007.

Net revenue for second quarter of 2007 was $108,850, a 22% increase compared to $89,319 in the second quarter of 2006. Net loss applicable to common stock for the second quarter of 2007 was $2,520,674, or $(0.05) per basic and diluted share, compared to a net loss of $1,686,164, or $(0.03) per basic and diluted share, in the second quarter of 2006. Year-over-year net loss increased by $834,510, or $(0.02) per basic and diluted share, primarily as a result of increased research and development expenses associated with clinical development and stock-based compensation expense Net loss during the most recent quarter was also affected by dividends and accretion associated with the Company's redeemable convertible preferred stock.

"We have made significant advancements in both our pharmaceutical and dermaceutical programs, and are pleased to have hit several milestones during the most recent quarter," stated Belinda Tsao-Nivaggioli, Avicena's Chief Executive Officer. "In terms of our clinical programs, we are extremely encouraged by the pace of enrollment in our NIH-funded Phase III Parkinson's disease trial, and received positive feedback from the FDA for advancing our Huntington's disease program into a Phase III trial in early 2008. Overall we are very pleased with how both our neurology and dermaceutical programs are progressing."

Research and development expenses for the second quarter of 2007 were $826,233, up from $175,191 in the second quarter of 2006 primarily based on clinical development costs to support late-stage clinical programs, including the supply of drugs and placebo for ongoing trials, as well as patent-related legal expenses. Selli
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... 2015 , ... The maximum number of shares proposed to be purchased in ... of unvested restricted stock). On June 29, 2015, the last trading day prior to ... on the OTCBB was $2.29 per share. , The tender offer will expire on ...
(Date:6/30/2015)... HAUPPAUGE, N.Y. , June 30, 2015  Custom ... provider, announced today that they are silver sponsors of ... an official PCDC sponsor, Custom is lending their support ... in low-income communities. Since its founding in ... for the primary care area.  PCDC has financed over ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... has accepted the position of vice president of instruction at Chippewa Valley Technical ... “I greatly appreciated the opportunity to lead SIUE during the past three years,” ...
(Date:6/29/2015)... Brooklyn, NY (PRWEB) , ... June 30, 2015 , ... ... Shimadzu and Perkin Elmer machines. Featuring 12 distinct peaks, the WAV-8 is the ... a machine is in spec deep into the NIR range. Previous spectrophotometer calibration standards, ...
Breaking Biology Technology:Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3
... Biovista Inc. today,announced that BVA-101, its drug targeting ... the MOG-induced Experimental Allergic,Encephalomyelitis (EAE) murine model of ... MS and is aimed at neuroprotection, was shown ... toxic effects in this well,established model of MS. ...
... announced that Merck & Co. Inc. has chosen ... collaboration agreement announced in June 2008 to apply ... novel small molecule leads against several drug targets.By ... a new multi-million member proprietary library of small ...
... manager of Xmark Opportunity Fund, L.P. and Xmark Opportunity Fund, Ltd., sent the following letter to the Board of Directors of Icagen, Inc. ... XMARK OPPORTUNITY PARTNERS, LLC, ... 90 Grove Street, ... 201, ...
Cached Biology Technology:Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis 2Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc. 2Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign 2
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
(Date:6/17/2015)... , and HILDEN, Germany , June 17, ... ; Frankfurt Prime Standard: QIA) today launched new Investigator ® ... forensic laboratories in the United States . ... simultaneously analyze multiple key genomic markers (short tandem repeats or ... Quality Sensor to evaluate the quality of DNA in each ...
(Date:6/16/2015)...  With the increasing number and severity of data ... The recent compromise of Federal employee data from ... within government agencies. HYPR Corp. announced today ... authenticator, has been submitted for testing and approval of ... for tamper proofing. The proliferation of ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Cruz Mountains two closely related species of mice share a ... lives. The California mouse ( Peromyscus californicus ) is characterized ... maniculatus ) is sexually promiscuous. Researchers at the University ... behavior impact the bacteria hosted by each species as well ...
... trials can be time-consuming, expensive and intrusive, but they ... Space Institute in Tullahoma have developed an invention that ... the virtual world. Called "digital Eye Bank," the ... eyes for researchers to use when testing their inventions. ...
... federal research effort to evaluate freshwater sustainability across the ... can be done to make the best use of ... the effects of climate change over the next 10 ... of Georgia are also part of the project. ...
Cached Biology News:Monogamy and the immune system 2Monogamy and the immune system 3Monogamy and the immune system 4Monogamy and the immune system 5University of Tennessee Space Institute researchers make clinical trials a virtual reality 2NC State leads national effort to evaluate fresh water sustainability in the southern US 2
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
IkappaB-alpha (112B2) Mouse mAb...
Human sIL-2R/CD25 ELI-PAIR Kit...
Biology Products: